Purpose Prostate-specific membrane antigen (PSMA) is a recognized target for imaging
prostate cancer. Here we present initial safety, biodistribution, and radiation dosimetry results …

Purpose: We have synthesized and evaluated in vivo 2-(3-{1-carboxy-5-[(6-[ 18 F]fluoro-pyridine-3-carbonyl)-amino]-pentyl}-ureido)-pentanedioic
acid, [ 18 F]DCFPyL, as a potential …

Purpose: Prostate-specific membrane antigen (PSMA) is a cell surface protein that is
overexpressed in prostate cancer, including hormone-refractory and metastatic disease. Our goal in …

Prostate-specific membrane antigen (PSMA) is a type II integral membrane protein
expressed on the surface of prostate cancer (PCa) cells, particularly in androgen-independent, …

The prostate-specific membrane antigen (PSMA) is increasingly recognized as a viable target
for imaging and therapy of cancer. We prepared seven 99m Tc/Re-labeled compounds by …

Purpose: Previously, we showed successful imaging of xenografts that express the prostate-specific
membrane antigen (PSMA) using small-animal positron emission tomography (PET) …

Gallium-68 is a generator-produced radionuclide for positron emission tomography (PET)
that is being increasingly used for radiolabeling of tumor-targeting peptides. Compounds [ 68 …

To extend our development of new imaging agents targeting the prostate-specific
membrane antigen (PSMA), we have used the versatile intermediate 2-[3-(5-amino-1-carboxy-pentyl)-…

Purpose Current standard of care conventional imaging modalities (CIM) such as X-ray
computed tomography (CT) and bone scan can be limited for detection of metastatic prostate …

Prostate cancer (PCa) is the second leading cause of cancer-related death in American men.
Positron emission tomography/computed tomography (PET/CT) with emerging …